| Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study AE Tjønna, SJ Lee, Ø Rognmo, TO Stølen, A Bye, PM Haram, ... Circulation 118 (4), 346-354, 2008 | 1767 | 2008 |
| Cardiovascular risk factors emerge after artificial selection for low aerobic capacity U Wisløff, SM Najjar, Ø Ellingsen, PM Haram, S Swoap, Q Al-Share, ... Science 307 (5708), 418-420, 2005 | 786 | 2005 |
| Aerobic interval training vs. continuous moderate exercise in the metabolic syndrome of rats artificially selected for low aerobic capacity PM Haram, OJ Kemi, SJ Lee, MØ Bendheim, QY Al-Share, HL Waldum, ... Cardiovascular research 81 (4), 723-732, 2009 | 325 | 2009 |
| Insulin acutely decreases hepatic fatty acid synthase activity SM Najjar, Y Yang, MA Fernström, SJ Lee, AM DeAngelis, GA Abou Rjaily, ... Cell metabolism 2 (1), 43-53, 2005 | 128 | 2005 |
| CEACAM1 modulates epidermal growth factor receptor–mediated cell proliferation GA Abou-Rjaily, SJ Lee, D May, QY Al-Share, AM DeAngelis, RJ Ruch, ... The Journal of clinical investigation 114 (7), 944-952, 2004 | 93 | 2004 |
| Forced hepatic overexpression of CEACAM1 curtails diet-induced insulin resistance QY Al-Share, AM DeAngelis, SG Lester, TA Bowman, SK Ramakrishnan, ... Diabetes 64 (8), 2780-2790, 2015 | 61 | 2015 |
| Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice SJ Lee, G Heinrich, L Fedorova, QY Al–Share, KJ Ledford, MA Fernstrom, ... Gastroenterology 135 (6), 2084-2095, 2008 | 53 | 2008 |
| Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease G Heinrich, HE Ghadieh, SS Ghanem, HT Muturi, K Rezaei, QY Al-Share, ... Frontiers in endocrinology 8, 8, 2017 | 43 | 2017 |
| Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice T Dai, GA Abou-Rjaily, QY Al-Share, Y Yang, MA Fernström, ... Journal of Biological Chemistry 279 (43), 45155-45161, 2004 | 42 | 2004 |
| Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects J Flarakos, Y Du, T Bedman, Q Al-Share, P Jordaan, P Chandra, ... Xenobiotica 46 (11), 986-1000, 2016 | 41 | 2016 |
| PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition SK Ramakrishnan, SS Khuder, QY Al-Share, L Russo, SL Abdallah, ... Journal of Biological Chemistry 291 (15), 8121-8129, 2016 | 37 | 2016 |
| Reduced hepatic carcinoembryonic antigen-related cell adhesion molecule 1 level in obesity G Heinrich, HT Muturi, K Rezaei, QY Al-Share, AM DeAngelis, ... Frontiers in endocrinology 8, 54, 2017 | 27 | 2017 |
| High-fat diet amplifies renal renin angiotensin system expression, blood pressure elevation, and renal dysfunction caused by Ceacam1 null deletion C Li, SA Culver, S Quadri, KL Ledford, QY Al-Share, HE Ghadieh, ... American Journal of Physiology-Endocrinology and Metabolism 309 (9), E802-E810, 2015 | 25 | 2015 |
| Superior Cardiovascular Effect Of Interval Training Versus Moderate Exercise In Patients With Metabolic Syndrome: 1279: Board# 42: May 30 11: 00 AM− 12: 30 PM AE Tjonna, PM Haram, SJ Lee, T Stolen, OJ Kemi, A Bye, JP Loennechen, ... Medicine & Science in Sports & Exercise 39 (5), s173, 2007 | 25 | 2007 |
| Hepatic CEACAM1 over-expression protects against diet-induced fibrosis and inflammation in white adipose tissue SG Lester, L Russo, SS Ghanem, SS Khuder, AM DeAngelis, EL Esakov, ... Frontiers in Endocrinology 6, 116, 2015 | 21 | 2015 |
| Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis [S] L Russo, HE Ghadieh, SS Ghanem, QY Al-Share, ZN Smiley, ... Journal of lipid research 57 (12), 2163-2175, 2016 | 20 | 2016 |
| Topical ocular TRPV1 antagonist SAF312 (Libvatrep) demonstrates safety, low systemic exposure, and no anesthetic effect in healthy participants K Stasi, Q Alshare, M Jain, M Wald, Y Li Translational Vision Science & Technology 11 (11), 15-15, 2022 | 4 | 2022 |
| Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety A Shatnawi, Z Kamran, Q Al-Share Personalized Medicine 20 (1), 65-86, 2023 | 2 | 2023 |
| The influence of adverse drug effects on health-related quality of life in chronic obstructive pulmonary disease patients SM Altawalbeh, BA Almomani, Q Alefan, S Mohammad Momany, ... International Journal of Pharmacy Practice 30 (5), 457-465, 2022 | 2 | 2022 |
| PPAR alpha Activation Reduces Hepatic CEACAM1 Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition SK Ramakrishnan, SS Khuder, QY Al-Share, L Russo, SL Abdallah, ... J. Biol. Chem 291, 8121-9, 2016 | 2 | 2016 |
Ulrik WisloffProfessor of Exercise PhysiologyVerified email at ntnu.no
